Cue Biopharma (CUE) Competitors $0.72 -0.02 (-2.79%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$0.76 +0.03 (+4.53%) As of 06:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. ANNX, VYGR, LYEL, TKNO, TNXP, SGMT, ACIU, ACRS, HUMA, and AVTEShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Annexon (ANNX), Voyager Therapeutics (VYGR), Lyell Immunopharma (LYEL), Alpha Teknova (TKNO), Tonix Pharmaceuticals (TNXP), Sagimet Biosciences (SGMT), AC Immune (ACIU), Aclaris Therapeutics (ACRS), Humacyte (HUMA), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Annexon Voyager Therapeutics Lyell Immunopharma Alpha Teknova Tonix Pharmaceuticals Sagimet Biosciences AC Immune Aclaris Therapeutics Humacyte Aerovate Therapeutics Cue Biopharma (NASDAQ:CUE) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Is CUE or ANNX more profitable? Annexon has a net margin of 0.00% compared to Cue Biopharma's net margin of -469.35%. Annexon's return on equity of -70.04% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-469.35% -230.13% -111.16% Annexon N/A -70.04%-57.67% Do analysts rate CUE or ANNX? Annexon has a consensus target price of $12.50, suggesting a potential upside of 396.03%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility and risk, CUE or ANNX? Cue Biopharma has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Does the media favor CUE or ANNX? In the previous week, Annexon had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Annexon and 0 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.89 beat Annexon's score of 0.95 indicating that Cue Biopharma is being referred to more favorably in the media. Company Overall Sentiment Cue Biopharma Very Positive Annexon Positive Do insiders and institutionals hold more shares of CUE or ANNX? 35.0% of Cue Biopharma shares are held by institutional investors. 10.8% of Cue Biopharma shares are held by insiders. Comparatively, 11.9% of Annexon shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, CUE or ANNX? Cue Biopharma has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.29M5.98-$40.67M-$0.56-1.29AnnexonN/AN/A-$138.20M-$1.29-1.95 SummaryAnnexon beats Cue Biopharma on 8 of the 15 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.10M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-1.2921.0377.1026.52Price / Sales5.98249.02451.8387.93Price / CashN/A45.4837.2260.63Price / Book2.589.5613.846.31Net Income-$40.67M-$53.02M$3.29B$271.37M7 Day Performance-5.67%-1.58%-0.75%0.57%1 Month Performance-11.79%2.82%3.84%6.20%1 Year Performance30.45%9.34%84.93%28.33% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma2.4624 of 5 stars$0.72-2.8%N/A+26.7%$57.10M$9.29M-1.2960Positive NewsANNXAnnexon2.329 of 5 stars$2.21+1.8%$12.50+465.6%-63.9%$238.45MN/A-1.7160VYGRVoyager Therapeutics3.9317 of 5 stars$4.26+0.5%$13.25+211.0%-31.7%$235.19M$80M-2.30100News CoveragePositive NewsAnalyst ForecastLYELLyell Immunopharma2.9921 of 5 stars$13.03+7.2%$15.00+15.1%-55.7%$233.42M$60K-0.54270Positive NewsGap DownTKNOAlpha Teknova2.8301 of 5 stars$4.35-0.2%$10.00+129.9%-7.8%$233.33M$37.74M-10.36240Positive NewsTNXPTonix Pharmaceuticals3.1254 of 5 stars$25.29-4.7%$70.00+176.8%+88.5%$232.65M$9.83M-0.6450News CoverageSGMTSagimet Biosciences3.3516 of 5 stars$7.03-1.1%$25.67+265.1%+82.0%$231.23M$2M-3.848ACIUAC Immune2.6478 of 5 stars$2.20-3.5%$10.00+354.5%-28.9%$228.94M$31.02M-3.79140Positive NewsACRSAclaris Therapeutics3.0369 of 5 stars$2.08-1.0%$8.71+319.0%+54.7%$227.50M$18.72M-1.52100Positive NewsHUMAHumacyte2.824 of 5 stars$1.41-1.4%$9.75+591.5%-70.7%$226.47M$1.57M-3.13150Analyst ForecastAVTEAerovate TherapeuticsN/A$7.77-0.1%N/A-89.3%$225.21MN/A-2.6020Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Annexon Alternatives Voyager Therapeutics Alternatives Lyell Immunopharma Alternatives Alpha Teknova Alternatives Tonix Pharmaceuticals Alternatives Sagimet Biosciences Alternatives AC Immune Alternatives Aclaris Therapeutics Alternatives Humacyte Alternatives Aerovate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
